Angiogenesis Inhibitors and Immunomodulation in Renal Cell Cancers: The Past, Present, and Future
Angiogenesis inhibitors have been adopted into the standard armamentarium of therapies for advanced-stage renal cell carcinomas (RCC), but more recently, combination regimens with immune checkpoint inhibitors have demonstrated better outcomes. Despite this, the majority of affected patients still ev...
Main Authors: | Lawrence Kasherman, Derrick Ho Wai Siu, Rachel Woodford, Carole A. Harris |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-03-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/14/6/1406 |
Similar Items
-
Angiogenesis: A Pivotal Therapeutic Target in the Drug Development of Gynecologic Cancers
by: Lawrence Kasherman, et al.
Published: (2022-02-01) -
Molecular Mechanisms of Resistance to Immunotherapy and Antiangiogenic Treatments in Clear Cell Renal Cell Carcinoma
by: Pablo Álvarez Ballesteros, et al.
Published: (2021-11-01) -
Cancer-Associated Angiogenesis: The Endothelial Cell as a Checkpoint for Immunological Patrolling
by: Antonio Giovanni Solimando, et al.
Published: (2020-11-01) -
Targeting Angiogenesis in Squamous Cell Carcinoma of the Head and Neck: Opportunities in the Immunotherapy Era
by: Nabil F. Saba, et al.
Published: (2022-02-01) -
Renal Carcinoma and Angiogenesis: Therapeutic Target and Biomarkers of Response in Current Therapies
by: Zoé Guillaume, et al.
Published: (2022-12-01)